Latest news with #TCR
Bloomberg
3 days ago
- Business
- Bloomberg
3i Seeks Pitches for Sale of Airport Services Firm TCR
By and Swetha Gopinath Save 3i Infrastructure Plc has asked for bank pitches as it prepares for a sale of airport ground support equipment company TCR, according to people familiar with the matter. The investment firm interviewed banks in recent days as it seeks to pick a sellside adviser, said the people, who asked not to be identified as the information is private.
Time of India
24-04-2025
- Business
- Time of India
Air India receives GDP certification for cargo business, setting new benchmark in pharma logistics
Live Events Partnering with GDP or CEIV-certified Cargo Terminal Operators at key airports Joining hands with container solution providers offering both active and passive temperature-controlled solutions Specialised trainings for cargo staff on IATA's Temperature Control Regulations (TCR) Procurement of essential equipment and tools such as thermal blankets and the introduction of a cool dolly at Delhi airport to minimise temperature deviations Robust Quality Systems: End-to-end documentation and monitoring processes to guarantee traceability and compliance with global standards. Global airline Air India has been awarded the Good Distribution Practices (GDP) certification for its Cargo business, reinforcing its commitment to delivering world-class logistics solutions for pharmaceutical India is the first and only Indian carrier, and among a few in Asia, to have achieved this global standard for excellence in handling, storage, and transportation of time and temperature-sensitive pharmaceutical GDP certification validates Air India's compliance with international guidelines for the safe and secure distribution of pharmaceuticals. In the financial year 2024-25, Air India transported over 4,000 tonnes of pharmaceuticals across the globe.'India is one of the world's key exporters of pharmaceutical products, demanding specialised logistics and precision for their transportation to other parts of the world. This certification provides a shot in the arm to our expertise and capabilities in this specialised space of logistics, assuring partners globally that we are fully equipped to safeguard the integrity of every shipment,' said Ramesh Mamidala, Head of Cargo, Air India in a its domestic route network, Air India's GDP-certified stations include major cargo hubs in Delhi, Mumbai, Hyderabad, Bangalore, Chennai, Ahmedabad, Indore, and Goa. Internationally, the certificate covers major gateways like New York (JFK), Newark (EWR), Chicago, London Heathrow, Frankfurt, Paris, and Amsterdam - ensuring seamless connectivity for pharmaceutical shipments both within India and its ability to transport vaccines, biologics, and other high-value medical goods, Air India has made significant investments in enhancing its pharmaceutical handling capabilities, including:Air India's GDP certification was awarded following a rigorous audit that included checks for quality manuals for pharmaceuticals, temperature-controlled warehouse and equipment, change control systems, documentation systems and processes, Corrective and Preventive Actions (CAPA) protocols, hygiene, safety and environment, as well as several assessments for risks and deviation management, etc. With a fast-modernising fleet and expanding global connectivity, Air India is poised to meet the evolving needs of the pharmaceutical sector while contributing to India's ambition to become a leading air cargo hub.
Yahoo
23-04-2025
- Business
- Yahoo
Artax Biopharma to present Phase 2a data on Nck modulator AX-158, establishing novel mechanism of action in autoimmune disease at the 2025 SID Annual Meeting
Late breaker abstract presentation to showcase clinical validation of first-in-class oral small molecule AX-158 in cohort of patients with psoriasis Full dataset to expand on previously announced topline results, reinforcing the potential of Nck modulation as a differentiated and transformative approach in autoimmune diseases CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Artax Biopharma, Inc., a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases, today announced that an abstract on the safety, efficacy and biomarker results of its Phase 2a study evaluating Nck modulator AX-158 in patients with psoriasis was accepted as a late breaking oral presentation at the Society for Investigative Dermatology (SID) Annual Meeting taking place May 7 – 10, 2025, in San Diego, California. Dr. Chris VanDeusen, Chief Scientific Officer, will present 'AX-158 Proof-of-Mechanism Safety Study: Evaluating a Novel T cell Receptor (TCR) Signal Modulator in Patients with Mild-to-Moderate Plaque Psoriasis (NCT05725057),' final abstract ID number LB1150, on May 9, 2025, in the Concurrent Mini-symposium 11: Late-Breaking Abstracts session taking place from 8:30 to 11:15 am PT in the Aqua D/E/F room of the Hilton San Diego Bayfront Hotel. Members of the Artax Biopharma management team will be present at the meeting. Please reach out via contact@artaxbiopharma to set up a meeting or request a copy of the presentation. About Artax Biopharma Artax Biopharma is a clinical-stage biotechnology company transforming the treatment of T Cell-driven autoimmune diseases. Artax's first-in-class oral small molecules aim to deliver immune system modulation without immunosuppression, potentially unlocking new treatment options as both monotherapy and in combination with other treatments. Artax Biopharma is based in the Boston area and raised funding from investors including Advent Life Sciences, Sound Bioventures, The Termeer Family Office, the Fuhrer Family Office and Columbus Venture Partners. For more info, see or follow us on LinkedIn. About Nck modulation We believe there is significant potential for Nck modulation to revolutionize treatment of T Cell-driven diseases. Immunomodulation maintains healthy control of the immune system, while addressing the underlying source of T Cell-driven diseases. Central to a well-functioning immune system is the T Cell Receptor (TCR). When TCR signaling becomes dysregulated, it causes T Cell-driven conditions, including autoimmune diseases. We believe the immunomodulation mechanism offered by our investigational agents holds broad potential to revolutionize how these T Cell-driven autoimmune diseases are addressed, while not impairing the ability of a patient's immune system to function properly. AX-158, our lead Nck modulator, has shown strong, broad cytokine modulation as well as modulation of mixed lymphocyte reactions. Good data on therapeutic efficacy with AX-158 were observed in murine models of self-antigen activation (EAE), with a prolonged pharmacodynamic effect in EAE, suggesting durable immune modulation. AX-158 showed no immunosuppression in models of strong antigen stimulation. Studies with AX-158 showed substantial preclinical evidence of activity in the Th2, Th17, Th1/Th0 pathways, suggesting that applications could be quite broad across the autoimmune space. For future clinical study inquiries: contact@ Contacts: Maria Nichol, DPhil, EPA, CPA Chief Business Officer mnichol@ Media: Madelin HawtinLifeSci Communicationsmhawtin@ in to access your portfolio
Associated Press
18-04-2025
- Health
- Associated Press
TCR Therapy Market Research Report 2025-2035: NY-ESO-1 Target Antigen is Likely to Dominate, Multiple Myeloma Segment Occupies the Largest Share
DUBLIN--(BUSINESS WIRE)--Apr 18, 2025-- The 'TCR Therapy Market Industry Trends and Global Forecasts to 2035, by Target Indication, Target Antigen, Key Players and Key Geographies' report has been added to offering. The global TCR therapy market is estimated to grow from USD 0.03 billion in the current year to USD 4.13 billion by 2035, at a CAGR of 51% during the forecast period, till 2035. Cancer continues to be one of the key areas of research and drug development within the pharmaceutical industry. In fact, in the past few years, the USFDA has approved more than 70 drugs for the treatment of different types of cancer. Given the challenges associated with conventional therapies, such as non-specificity and several side effects including gastrointestinal and cardiovascular toxicities, drug developers are actively investigating targeted anti-cancer therapies. Of these, modified T-cell receptor (TCR) based therapies have emerged as a promising option. TCR therapy utilizes genetically modified lymphocytes to target specific tumor markers. TCR therapies have been demonstrated to selectively target and eliminate tumor cells from the body of a host with minimal treatment-related side effects. Notably, over 110 clinical trials related to TCR therapies have been registered in the past ten years, indicating substantial research activity. Driven by a promising development pipeline and encouraging clinical trial results, the TCR-based therapy market is likely to witness significant growth in the mid to long-term. Global TCR Therapy Market: Key Segments Currently, Multiple Myeloma Segment Occupies the Largest Share of the Global TCR Therapy Market Based on target indication, the market is segmented into nasopharyngeal carcinoma, multiple myeloma, head and neck carcinoma, sarcoma, melanoma, acute myeloid leukemia, lung cancer, ovarian cancer and Merkel cell cancer. At present, the multiple myeloma segment holds the maximum share of the global TCR therapy market. It is worth highlighting that the TCR therapy market for nasopharyngeal carcinoma is likely to drive the market in the near future. NY-ESO-1 Target Antigen is Likely to Dominate the Global TCR Therapy Market During the Forecast Period Based on the target antigen, the market is segmented into NY-ESO-1, EBV and gp100. Currently, NY-ESO-1 antigen holds the maximum share within the TCR therapy market. This trend is unlikely to change in the near future. North America Accounts for the Largest Share of the Market Based on the key geographical regions, the market is segmented into North America, Europe, Asia-Pacific, Middle East and North Africa, Latin America, and the Rest of the world. Majority share is expected to be captured by drug developers based in North America and Europe. It is worth highlighting that, over the years, the market in Asia-Pacific is expected to grow at a higher CAGR. Global TCR Therapy Market: Key Insights The report delves into the current state of the global TCR therapy market and identifies potential growth opportunities within the industry. Some key findings from the report include: Primary Research Overview The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders: Some Key Players in the Global TCR Therapy Market include: Product Wise Sales Forecast Key Topics Covered: 1. PREFACE 2. EXECUTIVE SUMMARY 3. INTRODUCTION 3.1. Chapter Overview 3.2. Pillars of Cancer Therapy 3.3. Overview of Immunotherapies 3.4. Fundamentals of Cancer Immunotherapy 3.5. Classification of Cancer Immunotherapies 3.6. T Cell Immunotherapies 3.7. T-Cell Receptor (TCR)-based Cell Therapy 3.8. Concluding Remarks 4. TCR THERAPIES: MARKET LANDSCAPE 4.1. Chapter Overview 4.2. TCR Therapies: Overall Market Landscape 4.3. TCR Therapies: Overall Developer Landscape 5. POPULAR TARGET ANTIGEN ANALYSIS 5.1. Chapter Overview 5.2. Competitive Analysis: Popular Target Antigens of TCR Therapies 6. CLINICAL TRIAL ANALYSIS 6.1. Chapter Overview 6.2. Scope and Methodology 6.3. TCR Therapies: Clinical Trial Analysis 7. KEY OPINION LEADERS 7.1. Chapter Overview 7.2. Assumptions and Key Parameters 7.3. Methodology 7.4. TCR Therapies: Key Opinion Leaders 8. T CELL RECEPTOR THERAPY PROFILES 8.1. Chapter Overview 8.2. Kimmtrak / IMCgp100 / Tebentafusp (Immunocore) 8.3. GSK3377794 / NY-ESO-1C259 T-cells / Letetresgene Autoleucel (GlaxoSmithKline) 8.4. ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics) 8.5. JTCR016 (Juno Therapeutics) 8.6. TBI-1301 (Takara Bio) 8.7. MDG1011 (Medigene) 9. PARTNERSHIPS AND COLLABORATIONS 9.1. Chapter Overview 9.2. Partnership Models 9.3. TCR Therapies: Partnerships and Collaborations 10 FUNDING AND INVESTMENT ANALYSIS 10.1. Chapter Overview 10.2. Types of Funding 10.3. TCR Therapies: Funding and Investment Analysis 11. PATENT ANALYSIS 11.1. Chapter Overview 11.2. Scope and Methodology 11.3. TCR Therapies: Patent Analysis 12. CASE STUDY: CELL THERAPY MANUFACTURIN G 12.1. Chapter Overview 12.2. Overview of Cell Therapy Manufacturing 12.3. Cell Therapy Manufacturing Models 12.4. Scalability of Cell Therapy Manufacturing Processes 12.5. Types of Cell Therapy Manufacturers 12.6. Key Challenges Related to Manufacturing of Cell Therapies 12.7. Important Factors for Cell Therapy Manufacturing 12.8. Automation of Cell Therapy Manufacturing Processes 12.9. Cell Therapy Manufacturing Supply Chain 12.10. Comparison of Player Having In-House Capabilities and Contract Manufacturers 12.11. Regulatory Landscape 12.12. Future Perspectives 13. COST PRICE ANALYSIS 13.1. Chapter Overview 13.2. Factors Contributing to the High Price of Cell / Gene Therapies 13.3. Pricing Models for T-Cell Immunotherapies 13.4. Reimbursement related Considerations for T-cell Immunotherapies 14. MARKET FORECAST AND OPPORTUNITY ANALYSIS 14.1. Chapter Overview 14.2. Scope and Limitations 14.3. Key Assumptions and Forecast Methodology 14.4. Global TCR Therapy Market, 2022-2035 15. PROMOTIONAL ANALYSIS 15.1. Chapter Overview 15.2. Channels Used for Promotional Campaigns 15.3. Kimmtrak: Promotional Analysis 16. COMPANY PROFILES 16.1. Chapter Overview 16.2. Adaptimmune Therapeutics 16.3. Alaunos Therapeutics 16.4. Company Profiles 16.5. Bristol Myers Squibb 16.6. Cellular Biomedicine Group 16.7. Gilead Sciences 16.8. Cellular Biomedicine Group 16.9. GlaxoSmithKline 16.10. Immatics 16.11. Immunocore 16.12. Lion TCR 16.13. Takara Bio 16.14. Zelluna immunotherapy 17. CONCLUDING REMARKS 18. EXECUTIVE INSIGHTS 18.1. Chapter Overview 18.2. Celyad: Interview Transcript: Vincent Brichard, Vice President, Immuno-Oncology 18.3. Kite Pharma: Interview Transcript: Adrian Bot, Vice President, Scientific Affairs 18.4. Lion TCR: Interview Transcript: Victor Lietao Li, Co-Founder and Chief Executive Officer 18.5. TxCell: Interview Transcript: Miguel Forte, Chief Operating Officer 19. APPENDIX 1: TABULATED DATA 20. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS Additional Benefits For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. View source version on CONTACT: Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH ONCOLOGY SOURCE: Research and Markets Copyright Business Wire 2025. PUB: 04/18/2025 11:42 AM/DISC: 04/18/2025 11:41 AM
Yahoo
01-04-2025
- Business
- Yahoo
Zelluna ASA [ZLNA]: Ex reverse share split today
Oslo, Norway, 1 April 2025 Issuer name: Zelluna ASAEx. date: 1 April 2025Type of corporate action: Reverse share split Other information:Reverse split ratio – ten (10) old shares give one (1) new par value of NOK 1 per shareNew ISIN is NO 001 3524942. For further information, please contact: Hans Vassgård Eid, CFO, Zelluna ASAEmail: +47 482 48632 About Zelluna ASAZelluna's mission is to deliver transformative treatments with the capacity to cure advanced solid cancers, in a safe and cost-efficient manner, to patients on a global scale. The Company aims to do this by combining the most powerful elements of the immune system through pioneering the development of 'off the shelf' T cell receptor (TCR) guided natural killer (NK) cell therapies (TCR-NK). The TCR-NK platform offers a unique mechanism of action with broad cancer detection capability to overcome the diversity of tumours and will be used 'off the shelf' to overcome scaling limitations of current cell therapies. The lead program is a world's first MAGE-A4 targeting 'off the shelf' TCR-NK for the treatment of various solid cancers; a pipeline of earlier products follows. The Company is led by a management team of biotech entrepreneurs with deep experience in discovery through to clinical development of TCR and cell-based therapies including marketed products. Sign in to access your portfolio
